WallStSmart

Thermo Fisher Scientific Inc (TMO)vsViking Holdings Ltd (VIK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 595% more annual revenue ($45.20B vs $6.50B). VIK leads profitability with a 17.6% profit margin vs 15.1%. TMO trades at a lower P/E of 26.1x. VIK earns a higher WallStSmart Score of 66/100 (B-).

TMO

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 4.0Quality: 5.3
Piotroski: 3/9

VIK

Strong Buy

66

out of 100

Grade: B-

Growth: 9.3Profit: 8.5Value: 4.7Quality: 4.3
Piotroski: 6/9Altman Z: 0.16
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

TMOSignificantly Overvalued (-16.1%)

Margin of Safety

-16.1%

Fair Value

$408.60

Current Price

$465.00

$56.40 premium

UndervaluedFair: $408.60Overvalued

Intrinsic value data unavailable for VIK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TMO1 strengths · Avg: 9.0/10
Market CapQuality
$176.32B9/10

Large-cap with strong market position

VIK4 strengths · Avg: 9.0/10
Return on EquityProfitability
254.5%10/10

Every $100 of equity generates 255 in profit

EPS GrowthGrowth
226.6%10/10

Earnings expanding 226.6% YoY

Operating MarginProfitability
20.9%8/10

Strong operational efficiency at 20.9%

Revenue GrowthGrowth
27.8%8/10

Revenue surging 27.8% year-over-year

Areas to Watch

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.564/10

Expensive relative to growth rate

P/E RatioValuation
26.1x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

VIK3 concerns · Avg: 2.7/10
P/E RatioValuation
32.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
33.7x2/10

Trading at 33.7x book value

Altman Z-ScoreHealth
0.162/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : TMO

The strongest argument for TMO centers on Market Cap. Profitability is solid with margins at 15.1% and operating margin at 17.9%.

Bull Case : VIK

The strongest argument for VIK centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 17.6% and operating margin at 20.9%. Revenue growth of 27.8% demonstrates continued momentum.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Bear Case : VIK

The primary concerns for VIK are P/E Ratio, Price/Book, Altman Z-Score.

Key Dynamics to Monitor

TMO profiles as a mature stock while VIK is a growth play — different risk/reward profiles.

VIK carries more volatility with a beta of 1.57 — expect wider price swings.

VIK is growing revenue faster at 27.8% — sustainability is the question.

TMO generates stronger free cash flow (816M), providing more financial flexibility.

Bottom Line

VIK scores higher overall (66/100 vs 62/100), backed by strong 17.6% margins and 27.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Viking Holdings Ltd

CONSUMER CYCLICAL · TRAVEL SERVICES · USA

Viking Holdings Ltd engages in the passenger shipping and other forms of passenger transport in North America, the United Kingdom, and internationally. The company is headquartered in Pembroke, Bermuda.

Want to dig deeper into these stocks?